Lenvatinib, the free base form of the compound, is a small-molecule multityrosine kinase inhibitor that inhibits many receptor tyrosine kinases including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and stem cell factor (SCF). These growth factors are associated with many types of cancers. The compound can inhibit angiogenesis (the formation of new vessels), and tumor cell growth.